Form 4: Edwards Lifesciences Director Kieran Gallahue Reports Stock Grants in Form 4 Filing

Director Kieran Gallahue reports the acquisition of restricted stock units and a restricted stock award from Edwards Lifesciences on May 8, 2024.

Summary

• Kieran Gallahue, a director of Edwards Lifesciences Corp, filed a Form 4 disclosing changes in beneficial ownership.
• On May 8, 2024, Gallahue acquired 3,055 shares of common stock in the form of restricted stock units and 999 shares of common stock as a restricted stock award, both granted under the company's 2020 Nonemployee Directors Stock Incentive Program.
• The restricted stock units and the restricted stock award are scheduled to vest 100% after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders.
• Following these transactions, Gallahue directly owns 4,054 shares of common stock and indirectly owns 70,920 shares through a trust.

Sentiment

Score: 7

Explanation: The document reflects standard compensation practices and insider transactions, which are generally viewed neutrally to positively as they align director interests with shareholders.

Positives

• The grant of restricted stock units and restricted stock awards aligns the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

The restricted stock units and restricted stock award will vest 100% after the earlier of one year from the grant date or the company's next annual meeting of stockholders.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates standard compensation practices for board members.

Comparison to Industry Standards

• Stock grants to non-employee directors are a common practice in publicly traded companies, including those in the medical device industry such as Medtronic, Abbott, and Boston Scientific.
• The vesting schedules, typically one year or until the next annual meeting, are also standard.
• The size of the grant is likely determined by a number of factors including the size of the company, the director's role, and the company's overall compensation philosophy.

Stakeholder Impact

• The stock grants align the director's interests with those of the shareholders, potentially encouraging decisions that benefit the company's long-term value.
• The grants do not have a direct impact on employees, customers, suppliers, or creditors.

Key Dates